Table 4 VARI RNA and pathological QC
From: A multi-site feasibility study for personalized medicine in canines with Osteosarcoma
Patient ID | RNA QC | Pathology QC | |||||
|---|---|---|---|---|---|---|---|
A260/280 | RIN | % Viable tumor1 | % Viable non-Neoplastic tissue1 | % Necrotic tissue | VARI diagnosis | Clinical site diagnosis | |
| Â | (1st Cut / 2nd Cut) | ||||||
AH-301 | 2.27 | 8 | 75/75 | 5/10 | 20/15 | Chondrosarcoma | Chondrosarcoma |
FS 201 | 2.08 | 7.8 | 80/80 | 20/20 | 15/25 | Poorly differentiated tumor. Atypical Osteosarcoma | OSA |
RV 281 | 2.11 | 9.3 | 75/75 | 20/20 | 10/10 | Osteosarcoma | Chronic suppurative inflammation |
MH 101 | 1.84 | 5.52 | Â | Â | Â | No Pathology due to RNA QC failure | OSA |
TL-141 | 2.11 | 6.8 | 60/50 | 30/50 | 10/0 | Osteosarcoma. | OSA |
RB-181 | 2.11 | 7.5 | 80/85 | 10/5 | 10/10 | Osteosarcoma | OSA |
RB-182 | 2.07 | 8.5 | 60/60 | 20/30 | 20/10 | Osteosarcoma | OSA |
RB-183 | 2.09 | 6.8 | 90/80 | 10/10 | 0/10 | Osteosarcoma (FFPE) | OSA |
VS 121 | 2.06 | 6.4 | 90/95 | 5/0 | 5/5 | Osteosarcoma with a differential diagnosis of undifferentiated sarcoma. | OSA |
AZ-221 | 2.09 | 8.1 | 50/50 | 50/40 | 0/10 | Osteosarcoma (FFPE) | OSA |
RV-282 | Â | Â | Â | Â | Â | Sample lost due to shipping delay. | OSA |
NC-01 | 2.1 | 8 | 80/80 | 15/10 | 5/10 | Osteosarcoma. | OSA |
FS 202 | 2.09 | 8.53 | 60/65 | 30/25 | 10/10 | Osteosarcoma. (Frozen and FFPE) | OSA |
FS 203 | 2.03 | 7.2 | No evidence of tumor, values not recorded | No evidence of tumor (Frozen and FFPE) | Chronic inflammation | Â | Â |
RB 184 | 2.15 | 6.84 | 65/70 | 30/30 | 5/0 | Osteosarcoma. | OSA |
RB 185 | 1.8 | 6.9 | 90/75 | 5/20 | 5/15 | Osteosarcoma. (FFPE) | OSA |
RB 186 | 2.11 | 5.42 | Â | Â | Â | No Pathology due to RNA QC failure | OSA |
RV 283 | 2.09 | 8.4 | 60/60 | 40/40 | 0/0 | Undifferentiated sarcoma (FFPE). | OSA |
NC 162 | 2.08 | 7.4 | 0/0 | 70/70 | 30/30 | Normal tissue. | Not available |
RB 187 | 2.09 | 8.63 | 65/65 | 25/25 | 10/10 | Osteosarcoma | Suspected Synovial carcinoma |